RE:Relevant update…moving forwardfollowing is from oncy's press release. the 90 days (of which we are 30 days removed) was to get the "legal" agreement in place. see the second paragraph below: the actual p3 trial is not expected until early 2024. so, more waiting is the game absent some "real" news.
"We are delighted at being selected by the Precision Promise panel of experts," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech. "Our next step is to engage with stakeholders to finalize the protocol for Precision Promise's pelareorep-containing investigational treatment so that we can enter into this study.
Oncolytics expects to finalize the definitive agreements within the next 90 days and open the Precision Promise investigational treatment of pelareorep, checkpoint inhibitor, gemcitabine, and nab-paclitaxel in early 2024.